DOI QR코드

DOI QR Code

Tumour Suppressive Effects of WEE1 Gene Silencing in Breast Cancer Cells

  • Ghiasi, Naghmeh (Shiraz Institute for Cancer Research) ;
  • Habibagahi, Mojtaba (Department of Immunology, School of Medicine, Shiraz University of Medical Sciences) ;
  • Rosli, Rozita (Genetic Medicine Research Centre, Faculty of Medicine and Health Sciences) ;
  • Ghaderi, Abbas (Shiraz Institute for Cancer Research) ;
  • Yusoff, Khatijah (UPM-MAKNA Cancer Research Laboratory, Institute of Bioscience) ;
  • Hosseini, Ahmad (Shiraz Institute for Cancer Research) ;
  • Abdullah, Syahrilnizam (Genetic Medicine Research Centre, Faculty of Medicine and Health Sciences) ;
  • Jaberipour, Mansooreh (Shiraz Institute for Cancer Research)
  • Published : 2013.11.30

Abstract

Background: WEE1 is a G2/M checkpoint regulator protein. Various studies have indicated that WEE1 could be a good target for cancer therapy. The main aim of this study was to asssess the tumor suppressive potential of WEE1 silencing in two different breast cancer cell lines, MCF7 which carries the wild-type p53 and MDA-MB468 which contains a mutant type. Materials and Methods: After WEE1 knockdown with specific shRNAs downstream effects on cell viability and cell cycle progression were determined using MTT and flow cytometry analyses, respectively. Real-time PCR and Western blotting were conducted to assess the effect of WEE1 inhibition on the expression of apoptotic (p53) and anti-apoptotic (Bcl2) factors and also a growth marker (VEGF). Results: The results showed that WEE1 inhibition could cause a significant decrease in the viability of both MCF7 and MDA-MB-468 breast cancer cell lines by more than 50%. Interestingly, DNA content assays showed a significant increase in apoptotic cells following WEE1 silencing. WEE1 inhibition also induced upregulation of the apoptotic marker, p53, in breast cancer cells. A significant decrease in the expression of VEGF and Bcl-2 was observed following WEE1 inhibition in both cell lines. Conclusions: In concordance with previous studies, our data showed that WEE1 inhibition could induce G2 arrest abrogation and consequent cell death in breast cancer cells. Moreover, in this study, the observed interactions between the pro- and anti-apoptotic proteins and decrease in the angiogenesis marker expression confirm the susceptibility to apoptosis and validate the tumor suppressive effect of WEE1 inhibition in breast cancer cells. Interestingly, the levels of the sensitivity to WEE1 silencing in breast cancer cells, MCF7 and MDA-MB468, seem to be in concordance with the level of p53 expression.

Keywords

WEE1;Breast cancer;shRNA;viability inhibition;G2 arrest abrogation

References

  1. Amundson SA, Myers TG, Fornace AJ (1998). Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress. Oncogene, 17, 3287-99. https://doi.org/10.1038/sj.onc.1202576
  2. Bridges KA, Hirai H, Buser CA, et al (2011). MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Clin Cancer Res, 17, 5638-48. https://doi.org/10.1158/1078-0432.CCR-11-0650
  3. Bucher N, Britten CD (2008). G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer, 98, 523-8. https://doi.org/10.1038/sj.bjc.6604208
  4. Canman CE, Gilmer TM, Coutts SB, et al (1995). Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev, 9, 600-11. https://doi.org/10.1101/gad.9.5.600
  5. Carrassa L, Chila R, Lupi M, et al (2012). Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo. Cell Cycle, 11, 2507-17. https://doi.org/10.4161/cc.20899
  6. Castedo M, Perfettini JL, Roumier T, et al (2004). Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy. Oncogene, 23, 4362-70. https://doi.org/10.1038/sj.onc.1207572
  7. Chen PL, Chen YM, Bookstein R, et al (1990). Genetic mechanisms of tumor suppression by the human p53 gene. Science, 250, 1576-80. https://doi.org/10.1126/science.2274789
  8. Dixon H, Norbury CJ (2002). Therapeutic exploitation of checkpoint defects in cancer cells lacking p53 function. Cell Cycle, 1, 362-8. https://doi.org/10.4161/cc.1.6.257
  9. Foulkes WD, Stefansson IM, Chappuis PO, et al (2003). Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst, 95, 1482-5. https://doi.org/10.1093/jnci/djg050
  10. Fujisawa T, Watanabe J, Kamata Y, et al (2003). VEGF expression and its reguration by p53 gene transfection in endometrial carcinoma cells. Hum Cell, 16, 47-54. https://doi.org/10.1111/j.1749-0774.2003.tb00128.x
  11. Gottlieb E, Haffner R, King A, et al (1997). Transgenic mouse model for studying the transcriptional activity of the p53 protein: age- and tissue-dependent changes in radiation-induced activation during embryogenesis. EMBO J, 16, 1381-90. https://doi.org/10.1093/emboj/16.6.1381
  12. Gottlieb E, Oren M (1998). p53 facilitates pRb cleavage in IL-3-deprived cells: novel pro-apoptotic activity of p53. EMBO J, 17, 3587-96. https://doi.org/10.1093/emboj/17.13.3587
  13. Hirakawa S, Kodama S, Kunstfeld R, et al (2005). VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med, 201, 1089-99. https://doi.org/10.1084/jem.20041896
  14. Hortobagyi GN, de la Garza Salazar J, Pritchard K, et al (2005). The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer, 6, 391-401. https://doi.org/10.3816/CBC.2005.n.043
  15. Igarashi M, Nagata A, Jinno S, et al (1991). Wee1(+)-like gene in human cells. Nature, 353, 80-3. https://doi.org/10.1038/353080a0
  16. Iorns E, Lord CJ, Grigoriadis A, et al (2009). Integrated functional, gene expression and genomic analysis for the identification of cancer targets. PLoS One, 4, 5120. https://doi.org/10.1371/journal.pone.0005120
  17. Jiang M, Milner J (2003). Bcl-2 constitutively suppresses p53-dependent apoptosis in colorectal cancer cells. Genes Dev, 17, 832-7. https://doi.org/10.1101/gad.252603
  18. Kelly PN, Strasser A (2011). The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ, 18, 1414-24. https://doi.org/10.1038/cdd.2011.17
  19. Lacroix M, Toillon RA, Leclercq G (2006). p53 and breast cancer, an update. Endocr Relat Cancer, 13, 293-325. https://doi.org/10.1677/erc.1.01172
  20. Lai Z, Ferry KV, Diamond MA, et al (2001). Human mdm2 mediates multiple mono-ubiquitination of p53 by a mechanism requiring enzyme isomerization. J Biol Chem, 276, 31357-67. https://doi.org/10.1074/jbc.M011517200
  21. Mandal S, Berube G, Asselin E, et al (2007). A new platinum complex of triazine demonstrates G1 arrest with novel biological profile in human breast cancer cell line, MDA-MB-468. Bioorg Med Chem Lett, 17, 2139-45. https://doi.org/10.1016/j.bmcl.2007.01.116
  22. Mir SE, De Witt Hamer PC, Krawczyk PM, et al (2010). In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. Cancer Cell, 18, 244-57. https://doi.org/10.1016/j.ccr.2010.08.011
  23. Mukhopadhyay D, Tsiokas L, Sukhatme VP (1995). Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res, 55, 6161-5.
  24. Murrow LM, Garimella SV, Jones TL, et al (2010). Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome. Breast Cancer Res Treat 122, 347-57. https://doi.org/10.1007/s10549-009-0571-2
  25. Pal S, Datta K, Mukhopadhyay D (2001). Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res, 61, 6952-7.
  26. Porebska I, Wyrodek E, Kosacka M, et al (2006). Apoptotic markers p53, Bcl-2 and Bax in primary lung cancer. In Vivo, 20, 599-604.
  27. Prasad KA, Church JG (1997). EGF effects on p53 in MDA-468 human breast cancer cells: implications for G1 arrest. Cell Prolif, 30, 81-94. https://doi.org/10.1111/j.1365-2184.1997.tb00924.x
  28. Schlotter CM, Vogt U, Allgayer H, et al (2008). Molecular targeted therapies for breast cancer treatment. Breast Cancer Res, 10, 211. https://doi.org/10.1186/bcr2112
  29. Tibes R, Bogenberger JM, Chaudhuri L, et al (2012). RNAi screening of the kinome with cytarabine in leukemias. Blood, 119, 2863-72. https://doi.org/10.1182/blood-2011-07-367557
  30. Venkatachalam S, Tyner SD, Pickering CR, et al (2001). Is p53 haploinsufficient for tumor suppression? Implications for the p53+/- mouse model in carcinogenicity testing. Toxicol Pathol, 29, 147-54. https://doi.org/10.1080/019262301753178555
  31. Vousden KH, Lu X (2002). Live or let die: the cell’s response to p53. Nat Rev Cancer, 2, 594-604. https://doi.org/10.1038/nrc864
  32. Wang Y, Decker SJ, Sebolt-Leopold J (2004). Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis. Cancer Biol Ther, 3, 305-13. https://doi.org/10.4161/cbt.3.3.697

Cited by

  1. PVM/MA-shelled selol nanocapsules promote cell cycle arrest in A549 lung adenocarcinoma cells vol.12, pp.1, 2014, https://doi.org/10.1186/s12951-014-0032-x
  2. Involvement of multiple cellular pathways in regulating resistance to tamoxifen in BIK-suppressed MCF-7 cells vol.36, pp.9, 2015, https://doi.org/10.1007/s13277-015-3374-6
  3. Targeting protein kinase-b3 (akt3) signaling in melanoma vol.21, pp.3, 2017, https://doi.org/10.1080/14728222.2017.1279147
  4. MiR-503 enhances the radiosensitivity of laryngeal carcinoma cells via the inhibition of WEE1 vol.39, pp.10, 2017, https://doi.org/10.1177/1010428317706224